354 related articles for article (PubMed ID: 32066405)
1. PD-L1 and CD4 are independent prognostic factors for overall survival in endometrial carcinomas.
Zhang S; Minaguchi T; Xu C; Qi N; Itagaki H; Shikama A; Tasaka N; Akiyama A; Sakurai M; Ochi H; Satoh T
BMC Cancer; 2020 Feb; 20(1):127. PubMed ID: 32066405
[TBL] [Abstract][Full Text] [Related]
2. Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas.
Choi E; Chang MS; Byeon SJ; Jin H; Jung KC; Kim H; Lee KL; Kim W; Park JH; Kim KH; Kim JS; Choi IS; Han DS; Ahn HS; Heo SC
Diagn Pathol; 2020 Jun; 15(1):69. PubMed ID: 32498695
[TBL] [Abstract][Full Text] [Related]
3. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.
Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M
Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750
[TBL] [Abstract][Full Text] [Related]
5. Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.
Paulsen EE; Kilvaer TK; Khanehkenari MR; Al-Saad S; Hald SM; Andersen S; Richardsen E; Ness N; Busund LT; Bremnes RM; Donnem T
Clin Lung Cancer; 2017 Mar; 18(2):220-233.e8. PubMed ID: 27816392
[TBL] [Abstract][Full Text] [Related]
6. Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer.
Ojalvo LS; Thompson ED; Wang TL; Meeker AK; Shih IM; Fader AN; Cimino-Mathews A; Emens LA
Hum Pathol; 2018 Apr; 74():135-147. PubMed ID: 29288043
[TBL] [Abstract][Full Text] [Related]
7. The impact of programmed cell death-ligand 1 (PD-L1) and CD8 expression in grade 3 endometrial carcinomas.
Vagios S; Yiannou P; Giannikaki E; Doulgeraki T; Papadimitriou C; Rodolakis A; Nonni A; Vlachos A; Pavlakis K
Int J Clin Oncol; 2019 Nov; 24(11):1419-1428. PubMed ID: 31197557
[TBL] [Abstract][Full Text] [Related]
8. Prognostic implications of the tumor immune microenvironment and immune checkpoint pathway in primary central nervous system diffuse large B-cell lymphoma in the North Indian population.
Parkhi M; Chatterjee D; Bal A; Vias P; Yadav BS; Prakash G; Gupta SK; Radotra BD
APMIS; 2022 Feb; 130(2):82-94. PubMed ID: 34862664
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients.
Koh J; Ock CY; Kim JW; Nam SK; Kwak Y; Yun S; Ahn SH; Park DJ; Kim HH; Kim WH; Lee HS
Oncotarget; 2017 Apr; 8(16):26356-26367. PubMed ID: 28412752
[TBL] [Abstract][Full Text] [Related]
10. Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer.
Kim J; Kim S; Lee HS; Yang W; Cho H; Chay DB; Cho SJ; Hong S; Kim JH
Gynecol Oncol; 2018 May; 149(2):381-387. PubMed ID: 29572029
[TBL] [Abstract][Full Text] [Related]
11. Programmed Cell Death Ligand-1 (PDL-1) Correlates With Tumor Infiltration by Immune Cells and Represents a Promising Target for Immunotherapy in Endometrial Cancer.
Hecking T; Thiesler T; Halbe J; Otten L; Recker F; Gevensleben H; Müller T; Schiller C; Egger EK; Fimmers R; Stope MB; Kristiansen G; Mustea A
Anticancer Res; 2022 Mar; 42(3):1367-1376. PubMed ID: 35220229
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma.
Hatogai K; Kitano S; Fujii S; Kojima T; Daiko H; Nomura S; Yoshino T; Ohtsu A; Takiguchi Y; Doi T; Ochiai A
Oncotarget; 2016 Jul; 7(30):47252-47264. PubMed ID: 27322149
[TBL] [Abstract][Full Text] [Related]
13. Expression of programmed death ligand 1 is associated with poor prognosis in myeloid sarcoma patients.
Kawamoto K; Miyoshi H; Suzuki T; Kiyasu J; Yokoyama S; Sasaki Y; Sone H; Seto M; Takizawa J; Ohshima K
Hematol Oncol; 2018 Aug; 36(3):591-599. PubMed ID: 29602174
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of programed death ligand-1 and ligand-2 co-expression in salivary gland carcinomas.
Nakano T; Takizawa K; Uezato A; Taguchi K; Toh S; Masuda M
Oral Oncol; 2019 Mar; 90():30-37. PubMed ID: 30846173
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Significance of Programmed Death Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Axial Osteosarcoma.
Liu P; Xiao Q; Zhou B; Dai Z; Kang Y
World Neurosurg; 2019 Sep; 129():e240-e254. PubMed ID: 31128313
[TBL] [Abstract][Full Text] [Related]
16. HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1.
Jing CY; Fu YP; Yi Y; Zhang MX; Zheng SS; Huang JL; Gan W; Xu X; Lin JJ; Zhang J; Qiu SJ; Zhang BH
J Immunother Cancer; 2019 Mar; 7(1):77. PubMed ID: 30885276
[TBL] [Abstract][Full Text] [Related]
17. Retinoblastoma Is Characterized by a Cold, CD8+ Cell Poor, PD-L1- Microenvironment, Which Turns Into Hot, CD8+ Cell Rich, PD-L1+ After Chemotherapy.
Miracco C; Toti P; Gelmi MC; Aversa S; Baldino G; Galluzzi P; De Francesco S; Petrelli F; Sorrentino E; Belmonte G; Galimberti D; Bracco S; Hadjistilianou T
Invest Ophthalmol Vis Sci; 2021 Feb; 62(2):6. PubMed ID: 33538768
[TBL] [Abstract][Full Text] [Related]
18. Characterization of PD-L1 and PD-1 Expression and CD8+ Tumor-infiltrating Lymphocyte in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.
Larbcharoensub N; Mahaprom K; Jiarpinitnun C; Trachu N; Tubthong N; Pattaranutaporn P; Sirachainan E; Ngamphaiboon N
Am J Clin Oncol; 2018 Dec; 41(12):1204-1210. PubMed ID: 29672367
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes.
Rosenbaum MW; Bledsoe JR; Morales-Oyarvide V; Huynh TG; Mino-Kenudson M
Mod Pathol; 2016 Sep; 29(9):1104-12. PubMed ID: 27198569
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas.
Yang MW; Fu XL; Jiang YS; Chen XJ; Tao LY; Yang JY; Huo YM; Liu W; Zhang JF; Liu PF; Liu Q; Hua R; Zhang ZG; Sun YW; Liu DJ
World J Gastroenterol; 2019 Apr; 25(14):1684-1696. PubMed ID: 31011254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]